Silver Book Fact

Potential value of pneumonia vaccine

Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4 billion.

Weycker D, Sato R, Strutton D, Edelsberg J, et al. Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years. Vaccine. 2012; 30(36): 5437-44. http://www.sciencedirect.com/science/article/pii/S0264410X12008286

Reference

Title
Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years
Publication
Vaccine
Publication Date
2012
Authors
Weycker D, Sato R, Strutton D, Edelsberg J, et al
Volume & Issue
Volume 30, Issue 36
Pages
5437-44
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Cost of measles much higher than vaccine
    One case of measles can cost 23 times as much as a single vaccination to prevent it.  
  • Drastic reduction of morbidity from vaccine-preventable disease in 20th century
    In the 20th century, vaccines have reduced the morbidity from vaccine-preventable diseases by as much as 89–100%.  
  • Flu vaccine use can reduce illness risk in U.S. by 60%
    Recent studies from the Centers for Disease Control and Prevention show that the influenza vaccine can reduce the risk of illness in the overall U.S. population by around 60%. …  
  • Value of polio eradication
    Eradication of polio is estimated to produce savings to governments of $1.5 billion per year.  
  • Potential value of pneumonia vaccine
    Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…